

AMENDMENT

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of the Claims:

1.-54. (Canceled)

55. (Withdrawn – Currently Amended) A method of vaccinating a subject comprising;

obtaining a pharmaceutical composition of ~~claim 38~~ comprising an isolated hyperimmune serum-reactive antigen consisting of the amino acid sequence of: amino acids 6-28, 54-59, 135-147, 193-205, 274-279, 284-291, 298-308, 342-347, 360-366, 380-386, 408-425, 437-446, 457-464, 467-477, 504-510, 517-530, 535-543, 547-553, 562-569, 573-579, 592-600, 602-613, 626-631, 638-668 or 396-449 of SEQ ID NO: 32; and

administering the pharmaceutical composition to a subject;
wherein the subject is vaccinated.

56. (Withdrawn) The method of claim 55, wherein the subject is a human.

57. (Withdrawn) The method of claim 55, further defined as a method of treating and/or preventing *S. epidermidis* infection in the subject.

58. (Canceled)

59. (Withdrawn – Currently Amended) The method of claim 55, wherein the pharmaceutical composition comprises at least two different hyperimmune serum-reactive antigens ~~or fragments thereof.~~

60. (Canceled)

61. (Previously Presented) A pharmaceutical composition comprising an isolated hyperimmune serum-reactive antigen consisting of the amino acid sequence of: amino acids 6-28, 54-59, 135-147, 193-205, 274-279, 284-291, 298-308, 342-347, 360-366, 380-386, 408-425,

437-446, 457-464, 467-477, 504-510, 517-530, 535-543, 547-553, 562-569, 573-579, 592-600, 602-613, 626-631, 638-668 or 396-449 of SEQ ID NO: 32.

62. (Previously Presented) The pharmaceutical composition of claim 61, comprising the isolated hyperimmune serum-reactive antigen consisting of the amino acid sequence of amino acids 396-449 of SEQ ID NO: 32.

63. (New) The pharmaceutical composition of claim 61, further comprising at least two different hyperimmune serum-reactive antigens.

64. (New) The pharmaceutical composition of claim 61, further comprising an immunostimulatory substance.

65. (New) The pharmaceutical composition of claim 64, wherein the immunostimulatory substance is a polycationic polymer, an immunostimulatory deoxynucleotide (ODN), a peptide containing at least two LysLeuLys motifs, a neuroactive compound, alum, or a Freund's complete or incomplete adjuvant.

66. (New) The pharmaceutical composition of claim 65, wherein the polycationic polymer is a polycationic peptide.

67. (New) The pharmaceutical composition of claim 61, further defined as a vaccine.

68. (New) The pharmaceutical composition of claim 67, further defined as a vaccine for treatment and/or prevention of *S. epidermidis* infection.